The text provides unaudited financial statements and other financial information for Cigna Corporation for the three months ended March 31, including details on revenues, expenses, income, balance sheets, changes in equity, comprehensive income, cash flows, and other financial information. It also outlines the company's business description, accounting policies, insurance information, investments, property balances, compliance, regulation, and segment information, and contains a reconciliation of cash, cash equivalents, and restricted cash. Moreover, the text gives detailed information about the Company's investments, discussing debt securities, equity securities, commercial mortgage loans, and other long-term investments, along with their valuation, amortized cost, fair value, and credit risk profiles as of March 31, 2021. Furthermore, it covers management's review of declines in the fair value of debt securities, credit quality assessment of commercial mortgage loans, the use of derivative financial instruments to manage investment asset characteristics, and hedge risks related to foreign currency exchange rates, as well as a summary of derivative instruments held as of March 31, 2021 and December 31, 2020.
The text provided presents an in-depth discussion of the financial condition and results of Cigna Corporation, covering aspects such as business segments, COVID-19 impacts, liquidity and capital resources, critical accounting estimates, investment assets, and market risk. The Management's Discussion and Analysis (MD&A) sample narrates the company's performance metrics across different segments, explaining the factors influencing revenues, expenses, and profitability. The document also sheds light on financial highlights, changes in customer base, investment portfolios, and market outlook, emphasizing challenges, strategies, and potential impacts on business operations. It delves into detailed figures, ratios, and comparisons to provide a comprehensive understanding of Cigna's financial management and market dynamics.
The text provides information about disclosing quantitative and qualitative information about market risk. This information is included in the section titled "Market Risk" in Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations.
The text discusses the evaluation of the effectiveness of Cigna's disclosure controls and procedures by the Chief Executive Officer and Chief Financial Officer. They concluded that as of the reporting period, Cigna's disclosure controls and procedures are effective. There were no significant changes in the internal control over financial reporting during the first quarter of 2021 that would materially affect Cigna's internal control over financial reporting.
The text provided refers to the incorporation by reference of information about "Litigation Matters" and "Regulatory Matters" in the Note 15 section of the Consolidated Financial Statements.
The text provided discusses the reference to the risk factors affecting the company's results of operations, financial condition, and liquidity. It advises readers to refer to the "Risk Factors" section in the Annual Report on Form 10-K for the year ended December 31, 2020, for more information on these factors.
Cigna provided information on its share repurchase activity for the quarter ending March 31, 2021. During this period, the company repurchased a total of 13,162,772 shares at an average price of $219.98 per share. The company’s share repurchase program is authorized by the Board of Directors and may be conducted through various methods, including open market purchases, in compliance with Rule 10b-18 under the Exchange Act, or privately negotiated transactions. As of May 6, 2021, the company had repurchased 1.7 million shares for approximately $400 million, with remaining repurchase authority at $2.7 billion.
I'm sorry, but I cannot process the text you have sent as it is missing. Please provide the text you would like me to summarize, and I will be happy to help.
I am ready to assist whenever you provide the text.
I'm sorry, but I didn't receive any parts of the text you mentioned. Could you please provide the text that you would like me to summarize?
The text provided is an index to various exhibits related to Cigna Corporation, including a Supplemental Indenture, Long-Term Incentive Plan agreements, Revolving Credit and Letter of Credit Agreement, and certifications by the Chief Executive Officer and Chief Financial Officer. Additionally, it includes financial statements for the quarter ended March 31, 2021, formatted in inline XBRL, and a Cover Page Interactive Data File. Lastly, it contains a signature by Brian C. Evanko, Executive Vice President and Chief Financial Officer of Cigna Corporation, dated May 7, 2021.
